{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:03:41Z","timestamp":1789419821839,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s12325-020-01303-3","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T11:03:08Z","timestamp":1586948588000},"page":"2356-2372","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis"],"prefix":"10.1007","volume":"37","author":[{"given":"Janet","family":"Pope","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruta","family":"Sawant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namita","family":"Tundia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella X.","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia Z.","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A.","family":"Betts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,15]]},"reference":[{"issue":"2","key":"1303_CR1","first-page":"318","volume":"34","author":"JA Hodge","year":"2016","unstructured":"Hodge JA, Kawabata TT, Krishnaswami S, Clark JD, Telliez JB, Dowty ME, et al. The mechanism of action of tofacitinib\u2014an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2016;34(2):318\u201328.","journal-title":"Clin Exp Rheumatol"},{"key":"1303_CR2","unstructured":"European Medicines Agency (EMA). Summary of Product Characteristics. XELJANZ 5 mg and 10 mg film-coated tablets.https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xeljanz-epar-product-information_en.pdf. Accessed 2 Mar 2020."},{"issue":"1","key":"1303_CR3","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nrd.2017.267","volume":"17","author":"DM Schwartz","year":"2017","unstructured":"Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O'Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;17(1):78.","journal-title":"Nat Rev Drug Discov"},{"key":"1303_CR4","unstructured":"European Medicines Agency (EMA). Summary of Product Characteristics. Olumiant 2 mg and 4 mg film-coated tablets. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/olumiant-epar-product-information_en.pdf. Accessed 28 Jan 2020."},{"key":"1303_CR5","unstructured":"United States Food and Drug Administration (FDA). Highlights of prescribing information: OLUMIANT (baricitinib) tablets, for oral use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/207924s000lbl.pdf. Accessed 2 Mar 2020."},{"key":"1303_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","volume":"2","author":"JM Parmentier","year":"2018","unstructured":"Parmentier JM, Voss J, Graff C, Schwartz A, Argiriadi M, Friedman M, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018;2:23.","journal-title":"BMC Rheumatol"},{"key":"1303_CR7","unstructured":"United States Food and Drug Administration (FDA). Highlights of prescribing information: RINVOQ (upadacitinib) extended-release tablets, for oral use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/211675s000lbl.pdf. Accessed 2 Mar 2020."},{"issue":"10188","key":"1303_CR8","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","volume":"393","author":"JS Smolen","year":"2019","unstructured":"Smolen JS, Pangan AL, Emery P, Rigby W, Tanaka Y, Vargas JI, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019;393(10188):2303\u201311.","journal-title":"Lancet"},{"issue":"10139","key":"1303_CR9","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","volume":"391","author":"GR Burmester","year":"2018","unstructured":"Burmester GR, Kremer JM, Van den Bosch F, Kivitz A, Bessette L, Li Y, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10139):2503\u201312.","journal-title":"Lancet"},{"issue":"Supplement 2","key":"1303_CR10","first-page":"991","volume":"77","author":"Y Tanaka","year":"2018","unstructured":"Tanaka Y, Takeuchi T, Yamaoka K, Oribe M, Kawano M, Zhou Y, et al. A phase 2b\/3 randomised, placebo-controlled, double-blind study of upadacitinib, a selective jak1 inhibitor, in Japanese patients with active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs. Ann Rheum Dis. 2018;77(Supplement 2):991\u20132.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1303_CR11","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","volume":"76","author":"M Dougados","year":"2017","unstructured":"Dougados M, Van Der Heijde D, Chen YC, Greenwald M, Drescher E, Liu J, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: Results from the RA-BUILD study. Ann Rheum Dis. 2017;76(1):88\u201395.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1303_CR12","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/art.37816","volume":"65","author":"D Van Der Heijde","year":"2013","unstructured":"Van Der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65(3):559\u201370.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1303_CR13","doi-asserted-by":"publisher","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","volume":"159","author":"J Kremer","year":"2013","unstructured":"Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M, Martin-Mola E, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: A randomized trial. Ann Intern Med. 2013;159(4):253\u201361.","journal-title":"Ann Intern Med"},{"issue":"11","key":"1303_CR14","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1002\/art.41032","volume":"71","author":"R Fleischmann","year":"2019","unstructured":"Fleischmann R, Pangan AL, Song IH, Mysler E, Bessette L, Peterfy C, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind randomized controlled trial. Arthritis Rheumatol. 2019;71(11):1788\u2013800.","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"1303_CR15","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor PC, Keystone EC, Van Der Heijde D, Weinblatt ME, Del Carmen ML, Gonzaga JR, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376(7):652\u201362.","journal-title":"N Engl J Med"},{"issue":"10093","key":"1303_CR16","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","volume":"390","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017;390(10093):457\u201368.","journal-title":"Lancet"},{"issue":"6","key":"1303_CR17","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJMoa1112072","volume":"367","author":"RF Van Vollenhoven","year":"2012","unstructured":"Van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Meijide JAG, Wagner S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367(6):508\u201319.","journal-title":"N Engl J Med"},{"key":"1303_CR18","unstructured":"National Institute for Health Care and Excellence (NICE). Baricitinib for moderate to severe rheumatoid arthritis: Technology appraisal guidance. 2017; https:\/\/www.nice.org.uk\/guidance\/ta466. Accessed 2 Mar 2020."},{"key":"1303_CR19","unstructured":"National Institute for Health and Clinical Excellence (NICE). Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed: Technology appraisal guidance. 2016; https:\/\/www.nice.org.uk\/guidance\/ta375. Accessed 2 Mar 2020."},{"key":"1303_CR20","doi-asserted-by":"crossref","unstructured":"American College of Rheumatology Committee to Reevaluate Improvement C. A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response. Arthritis Rheum. 2007;57(2):193\u2013202.","DOI":"10.1002\/art.22552"},{"issue":"6","key":"1303_CR21","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/art.1780360601","volume":"36","author":"DT Felson","year":"1993","unstructured":"Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum. 1993;36(6):729\u201340.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1303_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.39480","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1\u201326.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"1303_CR23","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landew\u00e9 R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960\u201377.","journal-title":"Ann Rheum Dis"},{"key":"1303_CR24","unstructured":"National Institute for Health and Clinical Excellence (NICE). Rheumatoid arthritis in adults: Management (NICE guideline). 2018; https:\/\/www.nice.org.uk\/guidance\/ng100. Accessed 2 Mar 2020."},{"issue":"3","key":"1303_CR25","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41584-019-0170-5","volume":"15","author":"R van Vollenhoven","year":"2019","unstructured":"van Vollenhoven R. Treat-to-target in rheumatoid arthritis \u2014 are we there yet? Nat Rev Rheumatol. 2019;15(3):180\u20136.","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"1303_CR26","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1177\/0272989X12458724","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making. 2013;33(5):607\u2013617.","journal-title":"Med Decis Making."},{"issue":"1","key":"1303_CR27","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","volume":"15","author":"G R\u00fccker","year":"2015","unstructured":"R\u00fccker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol. 2015;15(1):58.","journal-title":"BMC Med Res Methodol"},{"issue":"11","key":"1303_CR28","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1136\/ard.2004.034371","volume":"64","author":"D van der Heijde","year":"2005","unstructured":"van der Heijde D, Klareskog L, Boers M, Landew\u00e9 R, Codreanu C, Bolosiu HD, et al. Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Ann Rheum Dis. 2005;64(11):1582\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1303_CR29","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1111\/1756-185X.13616","volume":"22","author":"GG Song","year":"2019","unstructured":"Song GG, Choi SJ, Lee YH. Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta\u2010analysis of randomized controlled trials. Int J Rheumat Dis. 2019;22(8):1563\u20131571.","journal-title":"Int J Rheumat Dis."},{"issue":"6","key":"1303_CR30","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s00393-018-0531-5","volume":"78","author":"SC Bae","year":"2019","unstructured":"Bae SC, Lee YH. Comparison of the efficacy and safety of tofacitinib and baricitinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. Z Rheumatol. 2019;78(6):559\u201367.","journal-title":"Z Rheumatol"},{"key":"1303_CR31","first-page":"358","volume":"78","author":"C Edwards","year":"2019","unstructured":"Edwards C, Sawant R, Du E, Cammarota J, Tang P, Garg V, et al. THU0168 A matching-adjusted indirect comparison (MAIC) of upadacitinib versus tofacitinib in csDMARD-IR patients with moderate to severe rheumatoid arthritis (RA). Annals of the Rheumatic Diseases 2019;78:358.","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"4","key":"1303_CR32","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.immuni.2012.03.014","volume":"36","author":"JJ O'Shea","year":"2012","unstructured":"O'Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity. 2012;36(4):542\u201350.","journal-title":"Immunity"},{"issue":"suppl 2","key":"1303_CR33","doi-asserted-by":"publisher","first-page":"ii11","DOI":"10.1136\/annrheumdis-2012-202576","volume":"72","author":"JJ O'Shea","year":"2013","unstructured":"O'Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A. Janus kinase inhibitors in autoimmune diseases. Ann Rheumat Dis. 2013;72(suppl 2):ii11\u2013ii5.","journal-title":"Ann Rheumat Dis"},{"issue":"8","key":"1303_CR34","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1517\/13543784.2014.918604","volume":"23","author":"P Norman","year":"2014","unstructured":"Norman P. Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014;23(8):1067\u201377.","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"1303_CR35","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.berh.2010.02.003","volume":"24","author":"RJ Riese","year":"2010","unstructured":"Riese RJ, Krishnaswami S, Kremer J. Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. Best Pract Res Clin Rheumatol. 2010;24(4):513\u201326.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"8","key":"1303_CR36","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s40262-015-0240-z","volume":"54","author":"F Namour","year":"2015","unstructured":"Namour F, Diderichsen PM, Cox E, Vayssiere B, Van der Aa A, Tasset C, et al. Pharmacokinetics and pharmacokinetic\/pharmacodynamic modeling of filgotinib (GLPG0634), a selective JAK1 inhibitor, in support of phase IIB dose selection. Clin Pharmacokinet. 2015;54(8):859\u201374.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"1303_CR37","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1136\/annrheumdis-2016-210105","volume":"76","author":"A Kavanaugh","year":"2017","unstructured":"Kavanaugh A, Kremer J, Ponce L, Cseuz R, Reshetko OV, Stanislavchuk M, et al. Filgotinib (GLPG0634\/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). Ann Rheum Dis. 2017;76(6):1009\u201319.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1303_CR38","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s40265-019-01131-y","volume":"79","author":"A Markham","year":"2019","unstructured":"Markham A, Keam SJ. Peficitinib: first global approval. Drugs. 2019;79(8):887\u201391.","journal-title":"Drugs"},{"issue":"Suppl 2","key":"1303_CR39","first-page":"969","volume":"77","author":"Z Li","year":"2018","unstructured":"Li Z, Hu J, Bao C, Li X, Li X, Xu J, et al. Efficacy and safety of baricitinib in MTX-IR patients with rheumatoid arthritis: 52 week results from a phase 3 study (RA-BALANCE). Ann Rheum Dis. 2018;77(Suppl 2):969\u201370.","journal-title":"Ann Rheum Dis"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01303-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-020-01303-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01303-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T10:24:32Z","timestamp":1618482272000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-020-01303-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,15]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["1303"],"URL":"https:\/\/doi.org\/10.1007\/s12325-020-01303-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,15]]},"assertion":[{"value":"17 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}